The Medical Letter on Drugs and Therapeutics
				
			FROM
ISSUE 1634
    
   			ISSUE 1634
October 4, 2021
                			
                		 Issue 1634
                		- Influenza Vaccine for 2021-2022
 - Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD
 - In Brief: Semglee - Insulin Glargine Interchangeable with Lantus
 - In Brief: New Warnings for Janus Kinase Inhibitors
 - Leuprolide Acetate (Fensolvi) for Central Precocious Puberty (online only)
 - Belimumab (Benlysta) for Lupus Nephritis (online only)
 
					Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
				
				Influenza Vaccine for 2021-2022
October 4, 2021 (Issue: 1634)
				Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication.1 Available influenza vaccines for the
2021-2022 season are listed in Table 2.
        			
        			
					
					
				
        			
				The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
				